PHGE · Biomx Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | $6.12M | $5.01M | $5.25M | - | $7.28M | $6.90M | $4.11M | - |
| SG&A | $1.61M | - | $2.41M | $2.42M | $2.51M | - | $3.25M | $2.83M | $2.68M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | $229.0K | - | - | - | $229.0K | - |
| Operating Income | ($1.30M) | - | ($8.54M) | ($7.43M) | ($7.76M) | - | ($11.33M) | ($9.72M) | ($6.79M) | - |
| Interest Expense | $192.0K | - | $5.0K | $850.0K | $850.0K | - | $574.0K | $745.0K | $850.0K | - |
| Income Tax | - | - | $3.0K | $2.0K | $1.0K | - | - | $5.0K | $5.0K | - |
| Net Income | ($19.14M) | - | ($9.17M) | ($6.04M) | ($7.66M) | - | $9.64M | $4.47M | ($17.33M) | - |
| EPS - Basic | $7.38 | - | $5.51 | $3.61 | $6.27 | - | ($5.89) | ($1.90) | $53.20 | - |
| EPS - Diluted | $7.38 | - | $5.51 | $3.61 | $6.27 | - | ($5.89) | $13.30 | $53.20 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.17M | $4.36M | $6.92M | $14.05M | $20.12M | $16.86M | $23.54M | $31.61M | $43.01M | $14.91M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $720.0K | $3.12M | $1.51M | $2.18M | $1.67M | $1.88M | $2.78M | $3.24M | $3.69M | $1.38M |
| Current Assets | $3.04M | $5.58M | $8.86M | $16.64M | $23.53M | $20.52M | $28.32M | $35.08M | $47.10M | $17.63M |
| Total Assets | $3.25M | $5.78M | $26.17M | $38.05M | $45.65M | $43.23M | $59.98M | $68.62M | $81.61M | $25.03M |
| Current Liabilities | $2.45M | $6.38M | $5.23M | $6.26M | $7.02M | $8.27M | $8.94M | $7.30M | $10.71M | $11.18M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $5.40M |
| Total Liabilities | $4.13M | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($881.0K) | ($1.30M) | $10.49M | $19.16M | $24.50M | $24.15M | $37.90M | $27.43M | ($9.54M) | $3.08M |
| Retained Earnings | ($236.04M) | ($216.90M) | ($203.56M) | ($194.39M) | ($188.36M) | ($180.70M) | ($180.70M) | ($175.83M) | ($180.30M) | ($162.97M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.41M) | - | - | - | ($8.71M) | - | - | - | ($11.36M) | - |
| Investing Cash Flow | ($996.0K) | - | - | - | $51.0K | - | - | - | $663.0K | - |
| Financing Cash Flow | $2.62M | - | - | - | $11.91M | - | - | - | $38.98M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | 0.1% | - | - |
| Return on assets | -588.7% | - | -35.0% | -15.9% | -16.8% | - | 16.1% | 6.5% | -21.2% | - |
| Return on equity | 2172.5% | - | -87.4% | -31.5% | -31.3% | - | 25.4% | 16.3% | 181.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.24 | 0.87 | 1.70 | 2.66 | 3.35 | 2.48 | 3.17 | 4.80 | 4.40 | 1.58 |
| Quick ratio | 1.24 | 0.87 | 1.70 | 2.66 | 3.35 | 2.48 | 3.17 | 4.80 | 4.40 | 1.58 |
| Cash ratio | 0.48 | 0.68 | 1.32 | 2.24 | 2.87 | 2.04 | 2.63 | 4.33 | 4.02 | 1.33 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | 1.75 |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.22 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -6.8x | - | -1707.2x | -8.7x | -9.1x | - | -19.7x | -13.1x | -8.0x | - |
| Equity multiplier | -3.69 | -4.44 | 2.50 | 1.99 | 1.86 | 1.79 | 1.58 | 2.50 | -8.55 | 8.12 |
| Liabilities / Assets | 1.27 | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 0.5x | - | 1.8x | 2.4x | 1.7x | - | - | 4.8x | 1.6x | - |
| P / B | - | - | 29.9x | 14.0x | 10.0x | - | 8.4x | 250.2x | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 83.3% | - | 24.6% | 23.6% | -14.3% | - | -45.3% | -60.1% | -9.3% | - |
| Net income growth (YoY) | -149.9% | - | - | - | 55.8% | - | - | - | -172.4% | - |
| EPS growth (YoY) | 17.7% | - | - | -72.9% | -88.2% | - | - | 10983.3% | 26500.0% | - |
| EPS CAGR (3y) | 232.9% | - | 146.0% | 143.5% | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -72.3% | -30.1% | - | 683.8% | 364.8% | 72.9% | - | -85.4% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing BiomX Inc. against the 5 most active filers in the same SIC group.